Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06911177 · ClinicalTrials.gov registry record · NA
Yeast Mannans and Stool Frequency
A NA study of Defecation Frequency, sponsored by University of Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06911177: Recruiting NA study of Defecation Frequency, sponsored by University of Florida.
NCT06911177 is a NA study of Defecation Frequency that is actively recruiting participants, run by University of Florida. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06911177, a NA study of Defecation Frequency, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Findings from an open-label pilot study of 20 adults suggested that supplementation with 15 g/day of yeast mannans was highly tolerable and demonstrated specific modulation of the microbiota and increased stool frequency in a subset of subjects reporting ≤1 stool per day at baseline. The primary aim of this randomized, double-blind, controlled trial is to determine if yeast mannan supplementation at 12 g/day will increase stool frequency in generally healthy adults reporting ≤1 stool per day. Secondary aims will determine the effect of yeast mannans on intestinal transit time, gastrointestinal symptoms, fecal microbiota composition, and urinary and fecal metabolomics.
Primary Outcome
Mean daily defecation frequency
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Yeast mannan
- DIETARY_SUPPLEMENT Control (placebo)
Study Locations (1)
Florida
- Department of Food Science and Human Nutrition - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT06911177 shows while recruiting
NCT06911177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Defecation Frequency appearing as the primary indexed condition, and to 2 interventions - of which Yeast mannan is the first listed.
NCT06911177 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06911177 about?
NCT06911177 is a clinical study titled "Yeast Mannans and Stool Frequency". Findings from an open-label pilot study of 20 adults suggested that supplementation with 15 g/day of yeast mannans was highly tolerable and demonstrated specific modulation of the microbiota and increased stool frequency in a subset of subjects reporting ≤1 stool per day at baseline. The primary aim...
What is the current status of trial NCT06911177?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-07-17. Estimated completion is 2026-06-30.
What conditions does trial NCT06911177 study?
This clinical trial studies the following conditions: Defecation Frequency.
What interventions are being tested in trial NCT06911177?
The interventions under investigation include: Yeast mannan (DIETARY_SUPPLEMENT), Control (placebo) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06911177?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06911177 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06911177's enrollment target sits among peer trials
70 1103rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI